Method for the alleviation of dyspareunia in women
View Patent ↗This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.
1. A method for alleviating dyspareunia during or after menopause, said method comprising administering to a woman in need thereof an effective amount of (deaminohydroxy)toremifene or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the (deaminohydroxy)toremifene is not a salt.
3. The method according to claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered orally.
4. The method according to claim 2 , wherein the (deaminohydroxy)toremifene is administered in a daily dose of 25 to 100 mg.
5. The method according to claim 2 , wherein the (deaminohydroxy)toremifene is administered in a daily dose of 60 mg.
6. The method according to claim 5 , wherein the (deaminohydroxy)toremifene is administered orally.
7. The method according to claim 1 , wherein the woman is a postmenopausal woman.
8. The method according to claim 2 , wherein the woman is a postmenopausal woman.
9. The method according to claim 6 , wherein the woman is a postmenopausal woman.
10. The method according to claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 30 to 90 mg.
11. The method according to claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt thereof is administered in a daily dose of 60 mg.
12. The method according to claim 1 , wherein the (deaminohydroxy)toremifene is administered orally in a daily dose of 60 mg.